Table 4. Multivariable analysis for... | American Society of Hematology

Table 4.

Multivariable analysis for survival

	OS			EFS*
	P	HR	95% CI	P	HR	95% CI
Age†	.969	1.001	0.972-1.030	.683	1.005	0.983-1.027
Male vs female	.498	0.809	0.440-1.491	.095	0.666	0.413-1.074
WBC count, ×10⁹/L†	.827	1.001	0.993-1.009	.246	0.996	0.989-1.003
NPM1^mut vs other genotypes	.0007	0.282	0.135-0.586	.0005	0.343	0.189-0.624
CBF vs other genotypes	.0180	0.253	0.081-0.790	.0037	0.268	0.110-0.652
Midostaurin vs placebo	.6212	0.859	0.470-1.569	.7693	0.930	0.570-1.515
Allogeneic HCT in first CR as a time-dependent covariate	.9282	0.968	0.476-1.969	.3652	0.639	0.243-1.683

	OS			EFS*
	P	HR	95% CI	P	HR	95% CI
Age†	.969	1.001	0.972-1.030	.683	1.005	0.983-1.027
Male vs female	.498	0.809	0.440-1.491	.095	0.666	0.413-1.074
WBC count, ×10⁹/L†	.827	1.001	0.993-1.009	.246	0.996	0.989-1.003
NPM1^mut vs other genotypes	.0007	0.282	0.135-0.586	.0005	0.343	0.189-0.624
CBF vs other genotypes	.0180	0.253	0.081-0.790	.0037	0.268	0.110-0.652
Midostaurin vs placebo	.6212	0.859	0.470-1.569	.7693	0.930	0.570-1.515
Allogeneic HCT in first CR as a time-dependent covariate	.9282	0.968	0.476-1.969	.3652	0.639	0.243-1.683

FLT3-ITD mutation status was available for 107 patients; 10 were NPM1^mut/FLT3-ITD^mut and 11 were NPM1^wt/FLT3-ITD^mut. Significant differences are indicated in bold.

EFS, considering complete remission within 1 or 2 induction cycles (n = 134).

†

Age and WBC were considered as continuous variables.

View Large

This Feature Is Available To Subscribers Only